Compare IDEXX Laboratories, Inc. (IDXX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs BlackRock TCP Capital Corp — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while BlackRock TCP Capital Corp trades at $4.01 (market cap $337.71M). The key difference: IDEXX Laboratories, Inc. is far larger — about 119.7× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and BlackRock TCP Capital Corp for 88 Days on average.
| IDXX | TCPC | |
|---|---|---|
Market Cap | $40.43B | $337.71M |
Volume | 692,164 | 436,109 |
Sector | Health | Financials |
52-Week High | $766.68 | $6.20 |
52-Week Low | $504.70 | $3.13 |
Typical Hold Time | 46 Days | 88 Days |
Enterprise Value | $41.32B | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
TCPC trades at $4.03, up 2.28% today, with a bullish technical signal from moving averages. The company reported negative revenue and net income for 2025 but beat Q2 2026 earnings expectations. Recent portfolio sales have reduced leverage and prompted a strategic review. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to negative profitability metrics and declining revenue trends, though recent strategic moves and technical strength offer potential upside. Key risks include ongoing negative cash flow, class action lawsuits, and execution challenges in the private credit market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
